G6PD

Across TCGA pan-cancer cohorts, G6PD mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated G6PD data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher G6PD mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated G6PD expression acts as an unfavorable survival marker.

PDAC, CCRCC, and LUAD are the cancer types where G6PD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.293	0.573	.002	42	view →
CCRCC	OS	Tertile	All	0.517	1.000	.001	32	view →
LUAD	OS	Quartile	II,III,IV	0.501	1.000	.001	25	view →
GBM	OS	Tertile	All	0.284	0.633	.004	8	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

G6PD–PDAC (DFS)

Open the PDAC breakdown →